Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene
Characterizing the immune microenvironment in HER2-overexpressing breast cancer has
the potential to furnish predictive and prognostic biomarkers that may be useful in routine
clinical decision-making. The host-tumour immune interface is emerging as a key aspect of
breast cancer biology that is likely to yield novel therapies in the near future.
the potential to furnish predictive and prognostic biomarkers that may be useful in routine
clinical decision-making. The host-tumour immune interface is emerging as a key aspect of
breast cancer biology that is likely to yield novel therapies in the near future.
Summary
Characterizing the immune microenvironment in HER2-overexpressing breast cancer has the potential to furnish predictive and prognostic biomarkers that may be useful in routine clinical decision-making. The host-tumour immune interface is emerging as a key aspect of breast cancer biology that is likely to yield novel therapies in the near future.
Lippincott Williams & Wilkins